The success rate of sorafenib can vary depending on several factors, including the type and stage of cancer being treated, individual patient characteristics, and how well the patient responds to the medication. In clinical trials, sorafenib has demonstrated efficacy in extending overall survival and delaying disease progression in patients with certain types of cancer, such as advanced kidney cancer (renal cell carcinoma) and liver cancer (hepatocellular carcinoma). However, the success rate can vary from person to person, and not all patients will experience the same benefits. It's important for individuals considering sorafenib treatment to discuss the potential risks and benefits with their healthcare provider to make an informed decision about their care. Overall, sorafenib represents a valuable option in the treatment of certain cancers, offering hope and improved outcomes for many patients.